Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Pipeline Review, H1 2018
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Pipeline Review, H1 2018
SUMMARY
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase – Pipeline Review, H1 2018, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 3, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology, Infectious Disease, Oncology, Respiratory, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones and Toxicology which include indications Ocular Hypertension, Glaucoma, Diabetic Nephropathy, Pulmonary Hypertension, Sickle Cell Disease, Tinea pedis (Athlete Foot), Acute Respiratory Distress Syndrome, Alzheimer's Disease, Carotid Artery Stenosis, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Neuropathic Pain, Diastolic Heart Failure, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Lung Infections, Onychomycosis (Tinea Unguium), Open-Angle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Stroke, Systemic Sclerosis (Scleroderma), Systolic Heart Failure, Vascular Dementias and Wounds.
Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase – Pipeline Review, H1 2018, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 3, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology, Infectious Disease, Oncology, Respiratory, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones and Toxicology which include indications Ocular Hypertension, Glaucoma, Diabetic Nephropathy, Pulmonary Hypertension, Sickle Cell Disease, Tinea pedis (Athlete Foot), Acute Respiratory Distress Syndrome, Alzheimer's Disease, Carotid Artery Stenosis, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Neuropathic Pain, Diastolic Heart Failure, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Lung Infections, Onychomycosis (Tinea Unguium), Open-Angle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Stroke, Systemic Sclerosis (Scleroderma), Systolic Heart Failure, Vascular Dementias and Wounds.
Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Companies Involved in Therapeutics Development
Bayer AG
Boehringer Ingelheim GmbH
Ironwood Pharmaceuticals Inc
NicOx SA
Novan Inc
SynZyme Technologies LLC
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Drug Profiles
A-8R – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1101042 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1237592 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-546544 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-703704 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IW-1701 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IW-6463 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IWP-953 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naproxcinod – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-1653 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-429 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-470 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-667 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
praliciguat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
riociguat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate sGC for Osteoporosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Hypertension and Parenchymal Hemorrhage – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate sGC for Liver Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOPN-53 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vacno – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vericiguat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Dormant Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Discontinued Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Product Development Milestones
Featured News & Press Releases
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease
Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects
Oct 31, 2017: Novoteris Investigator Receives Health Canada Clearance to Start a Phase 2a Clinical Trial of its Thiolanox® Nitric Oxide for the Treatment of Non-Tuberculous Mycobacteria
Oct 24, 2017: Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest Physicians
Jun 29, 2017: Bayer Now Enrolling Patients into a Global Pulmonary Arterial Hypertension Study
Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis
May 19, 2017: Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2017 International Conference
May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017
May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017
Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
Jan 26, 2017: Bayer and Merck to Present Riociguat Data in Rare Pulmonary Diseases at the Annual World Congress of the Pulmonary Vascular Research Institute
Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Companies Involved in Therapeutics Development
Bayer AG
Boehringer Ingelheim GmbH
Ironwood Pharmaceuticals Inc
NicOx SA
Novan Inc
SynZyme Technologies LLC
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Drug Profiles
A-8R – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1101042 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1237592 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-546544 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-703704 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IW-1701 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IW-6463 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IWP-953 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naproxcinod – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-1653 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-429 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-470 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-667 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
praliciguat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
riociguat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate sGC for Osteoporosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Hypertension and Parenchymal Hemorrhage – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate sGC for Liver Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOPN-53 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vacno – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vericiguat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Dormant Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Discontinued Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Product Development Milestones
Featured News & Press Releases
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease
Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects
Oct 31, 2017: Novoteris Investigator Receives Health Canada Clearance to Start a Phase 2a Clinical Trial of its Thiolanox® Nitric Oxide for the Treatment of Non-Tuberculous Mycobacteria
Oct 24, 2017: Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest Physicians
Jun 29, 2017: Bayer Now Enrolling Patients into a Global Pulmonary Arterial Hypertension Study
Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis
May 19, 2017: Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2017 International Conference
May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017
May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017
Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
Jan 26, 2017: Bayer and Merck to Present Riociguat Data in Rare Pulmonary Diseases at the Annual World Congress of the Pulmonary Vascular Research Institute
Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
Pipeline by NicOx SA, H1 2018
Pipeline by Novan Inc, H1 2018
Pipeline by SynZyme Technologies LLC, H1 2018
Pipeline by Topadur Pharma AG, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
Pipeline by NicOx SA, H1 2018
Pipeline by Novan Inc, H1 2018
Pipeline by SynZyme Technologies LLC, H1 2018
Pipeline by Topadur Pharma AG, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Bayer AG
Boehringer Ingelheim GmbH
Ironwood Pharmaceuticals Inc
NicOx SA
Novan Inc
SynZyme Technologies LLC
Topadur Pharma AG
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Bayer AG
Boehringer Ingelheim GmbH
Ironwood Pharmaceuticals Inc
NicOx SA
Novan Inc
SynZyme Technologies LLC
Topadur Pharma AG
